FDA Approves LEVOCARNITINE — Baxter Healthcare Corporation
Baxter Healthcare Corporation has received FDA approval for the intravenous formulation of levcarnitine under ANDA217896, advancing the company’s generic pipeline. The approval provides a potential new commercial avenue that could intensify pricing competition in the critical care intravenous nutritional market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed